Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;122(26):e2425384122.
doi: 10.1073/pnas.2425384122. Epub 2025 Jun 25.

Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets

Affiliations

Genome-scale knockout simulation and clustering analysis of drug-resistant breast cancer cells reveal drug sensitization targets

JinA Lim et al. Proc Natl Acad Sci U S A. 2025 Jul.

Abstract

Anticancer chemotherapy is an essential part of cancer treatment, but the emergence of resistance remains a major hurdle. Metabolic reprogramming is a notable phenotype associated with the acquisition of drug resistance. Here, we develop a computational framework that predicts metabolic gene targets capable of reverting the metabolic state of drug-resistant cells to that of drug-sensitive parental cells, thereby sensitizing the resistant cells. The computational framework performs single-gene knockout simulation of genome-scale metabolic models that predicts genome-wide metabolic flux distribution in drug-resistant cells, and clusters the resulting knockout flux data using uniform manifold approximation and projection, followed by k-means clustering. From the clustering analysis, knockout genes that lead to the flux data near that of drug-sensitive cells are considered drug sensitization targets. This computational approach is demonstrated using doxorubicin- and paclitaxel-resistant MCF7 breast cancer cells. Drug sensitization targets are further refined based on proteome and metabolome data, which generate GOT1 for doxorubicin-resistant MCF7, GPI for paclitaxel-resistant MCF7, and SLC1A5 as a common target. These targets are experimentally validated where treating drug-resistant cancer cells with small-molecule inhibitors results in increased sensitivity of drug-resistant cells to doxorubicin or paclitaxel. The applicability of the developed framework is further demonstrated using drug-resistant triple-negative breast cancer cells. Taken together, the computational framework predicts drug sensitization targets in an intuitive and cost-efficient manner and can be applied to overcome drug-resistant cells associated with various cancers and other metabolic diseases.

Keywords: anticancer drug resistance; drug sensitization; genome-scale metabolic model; metabolic reprogramming; single-gene knockout simulation.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement:Patent title: Method for screening key regulatory genes in anticancer drug resistance by using metabolic network model comparison. Korean patent applied (10-2024-0051437).

Similar articles

References

    1. Gottesman M. M., Fojo T., Bates S. E., Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48–58 (2002). - PubMed
    1. Szakacs G., Paterson J. K., Ludwig J. A., Booth-Genthe C., Gottesman M. M., Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219–234 (2006). - PubMed
    1. Kroger N., Achterrath W., Hegewisch-Becker S., Mross K., Zander A. R., Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev. 25, 279–291 (1999). - PubMed
    1. Murray S., Briasoulis E., Linardou H., Bafaloukos D., Papadimitriou C., Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 38, 890–903 (2012). - PubMed
    1. Zaal E. A., Berkers C. R., The influence of metabolism on drug response in cancer. Front. Oncol. 8, 500 (2018). - PMC - PubMed

LinkOut - more resources